Briefs
This advisory brief incorporates learnings from TGaS Advisors’ 2022 Fall Summit, which brought together the industry’s top commercial operations, market access and medical affairs executives to discuss the hottest trends, address concerns and prepare for future challenges.
More than 200 individuals from 100 emerging, mid-tier and large-tier biopharmaceutical companies attended function-specific sessions across the Commercial, Market Access and Medical Affairs ecosystem. Leaders shared perspectives, made recommendations and collectively thought through alternative paths forward relative to key decisions to be made…
Read Now
Blog
Published November 7, 2022
Executive Summary
The Oncology Care Model (OCM) was designed to test whether financial incentives can improve care and lower Medicare (U.S. federal health insurance program) spending, emphasizing value-based care within oncology treatment. This model supported a wide range of services such as high-cost emergency room visits, 24/7 access to clinicians and specialized, patient-specific coordinated care plans.
The Enhancing Oncology Model (EOM) builds on the structure of OCM with an increased focus on managing provider risk, promoting patient-centric care and addressing…
Read Now
Webinars
Available On Demand
Trinity invites life sciences executives to join us for a dynamic discussion on the most common high-impact challenges inherent in Business Development:
What contributes to inaccurate pricing and market access assumptions in the quick-paced Business Development process?
How do you de-risk pricing and access at each stage of the diligence process?
Chad Faulkner, Partner in Trinity’s Strategic Advisory practice, will host this session and moderate a panel with special guests Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value,…
Watch Now
Webinars
Available On Demand
What are the latest incentive compensation trends that you need to know to remain competitive in the quest for talent?
TGaS Advisors, a division of Trinity Life Sciences, explored this question as part of our 12th Annual Incentive Compensation Landscape – the most comprehensive study of its kind in the life sciences industry. We surveyed Incentive Compensation (IC) leaders at 54 life sciences companies of all sizes to gain their perspectives on current trends and best practices in incentive compensation…
Watch Now
Blog
Published October 31, 2022
Executive Summary:
Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz) was first proposed in March 2022 by Health Minister Professor Karl Lauterbach to help tackle the country’s economic deficit
Updated (January 13, 2023): The act was adopted by the Bundestag (German Federal Parliament) in October 2022. Most reforms have entered into force in November 2022, with the exception of the reduced sales threshold for orphan drugs (December 2022), the increased manufacturer rebate (January 2023) and the additional rebate…
Read Now
Scientific Publications
Autoimmune screening panel (ASP) is routinely ordered as a part of diagnostic work-up in people with suspected multiple sclerosis (MS). However, data on prevalence and significance of ASP seropositivity in MS is scarce.
Authors
D. Bandari, M. Adamson, M. Bowman, A. Gutierrez, A. Athavale, B. Oak, N. Hadker, F. Branco, C. Geremakis, J. B. Lewin, S. L. Shankar
Journal
ECTRIMS 2022
View publication…
Read Now
White Papers
Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans.
Coverage of DTx to date has been limited and the outlook for it is unclear. We spoke to four medical and pharmacy directors from large payer organizations…
Read Now
Blog
Published October 14, 2022
Executive Summary
The “ANS rol” defines the minimum mandatory coverage of services (diagnostics, procedures, and treatments) in the private sector. While private providers could opt to provide coverage beyond this list, in practice, the “ANS rol” has traditionally been seen as the maximum coverage that would be provided with anything beyond the “ANS Rol” being typically rejected
Law 14.454/2022 published in September 2022 establishes that the “ANS Rol” will dictate the minimum coverage that private payers need to provide, but…
Read Now
Webinars
Available On Demand
Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets.
Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…
Watch Now
White Papers
With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…
Read Now
